Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

JAK2 617V>F mutation occurs in a homozygous state in 25% to 30% of patients with polycythemia vera (PV) and 2% to 4% with essential thrombocythemia (ET). Whether homozygosity associates with distinct clinical phenotypes is still under debate. This retrospective multicenter study considered 118 JAK2 617V>F homozygous patients (104 PV, 14 ET) whose clinical characteristics were compared with those of 587 heterozygous and 257 wild-type patients. Irrespective of their clinical diagnosis, homozygous patients were older, displayed a higher leukocyte count and hematocrit value at diagnosis, and presented larger spleen volume. Aquagenic pruritus was significantly more common among homozygous PV patients. JAK2 617V>F homozygosity associated with more frequent evolution into secondary myelofibrosis in both PV and ET. After adjustment for sex, age, leukocyte count, and previous thrombosis in a multivariate analysis, homozygous ET patients displayed a significantly higher risk of cardiovascular events (hazard ratio [HR] 3.97, 95% confidence interval [CI] 1.34-11.7; P = .013) than wild-type (HR = 1.0) or heterozygous patients (HR = 1.49). No significant association of JAK2 617V>F homozygosity with thrombosis risk was observed in PV. Finally, JAK2 617V>F homozygous patients were more likely to receive chemotherapy for control of disease. We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.

[1]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[2]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[3]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[4]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[5]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.

[6]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[7]  A. Axelrad,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974, The New England journal of medicine.

[8]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[9]  G. Thomas,et al.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. , 2006, Blood.

[10]  R. Mesa,et al.  A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. , 2006, Haematologica.

[11]  T. Barbui,et al.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. , 2007, Haematologica.

[12]  R. V. van Etten,et al.  Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F , 2006, PloS one.

[13]  T. Barbui,et al.  Risk-adapted therapy in essential thrombocythemia and polycythemia vera. , 2005, Blood reviews.

[14]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[15]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[16]  R. Gabriel.  Letter: Renal biopsy: oversophistication. , 1974, The New England journal of medicine.

[17]  R. Hoffman,et al.  Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. , 2006, Blood.

[18]  T. Barbui,et al.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Barbui,et al.  Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2004, Haematologica.

[20]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[21]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[22]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[23]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[24]  W. Dameshek.  Editorial: Some Speculations on the Myeloproliferative Syndromes , 1951 .

[25]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[26]  D. Gilliland,et al.  Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia , 2005, British journal of haematology.

[27]  B. Druker,et al.  Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.

[28]  M. Wadleigh,et al.  JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance , 2005, British journal of haematology.

[29]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[30]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[31]  L. Wasserman,et al.  Polycythemia Vera and the Myeloproliferative Disorders , 1995 .

[32]  M. Wadleigh,et al.  The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.

[33]  Gruppo Italiano Studio Policitemia.  Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years , 1995, Annals of Internal Medicine.

[34]  M. Cazzola,et al.  Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. , 2005, Haematologica.

[35]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[36]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[37]  T. Barbui,et al.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. , 2007, Blood.

[38]  D. Linch,et al.  Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. , 2007, Blood.

[39]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[40]  R. Petitt.  Polycythemia Vera and the Myeloproliferative Disorders , 1995 .

[41]  Prchal Jf,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974 .

[42]  A. Tefferi,et al.  JAK2 mutations in myeloproliferative disorders. , 2005, The New England journal of medicine.

[43]  P. Guglielmelli,et al.  A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. , 2006, Leukemia.